{"filing":{"accession_number":"0001005286-26-000026","cik":"0001005286","ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. \\DE\\","form":"8-K","filing_date":"2026-07-02","report_date":null,"primary_document":"lfcr-20260629.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528626000026/lfcr-20260629.htm"},"events":[{"id":16006,"run_id":14278,"accession_number":"0001005286-26-000026","anchor_item_number":"7.01","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"The disclosure announces redemption notices for approximately 49,263 shares of Series A Redeemable Convertible Preferred Stock with a total redemption obligation of ~$52.1 million due December 28, 2026. This represents a material financial obligation that the company must address through strategic alternatives (debt/equity financing, asset sales, or lender consents). While the redemption right was previously disclosed, the actual exercise of that right and the company's liquidity constraints ($38.1M available vs. $52.1M obligation) constitute a material financial event affecting the company's capital structure and near-term financing needs.","company_name":"LIFECORE BIOMEDICAL, INC. \\DE\\","ticker":"LFCR","filing_date":"2026-07-02","form":"8-K","submitted_at":null,"items":[{"id":13953,"accession_number":"0001005286-26-000026","item_number":"7.01","item_title":"Regulation FD.","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces redemption notices for approximately 49,263 shares of Series A Redeemable Convertible Preferred Stock with a total redemption obligation of ~$52.1 million due December 28, 2026. This represents a material financial obligation that the company must address through strategic alternatives (debt/equity financing, asset sales, or lender consents). While the redemption right was previously disclosed, the actual exercise of that right and the company's liquidity constraints ($38.1M available vs. $52.1M obligation) constitute a material financial event affecting the company's capital structure and near-term financing needs.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T21:18:36.444697+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13953,"accession_number":"0001005286-26-000026","item_number":"7.01","item_title":"Regulation FD.","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces redemption notices for approximately 49,263 shares of Series A Redeemable Convertible Preferred Stock with a total redemption obligation of ~$52.1 million due December 28, 2026. This represents a material financial obligation that the company must address through strategic alternatives (debt/equity financing, asset sales, or lender consents). While the redemption right was previously disclosed, the actual exercise of that right and the company's liquidity constraints ($38.1M available vs. $52.1M obligation) constitute a material financial event affecting the company's capital structure and near-term financing needs.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T21:18:36.444697+00:00","company_name":"LIFECORE BIOMEDICAL, INC. \\DE\\","ticker":"LFCR","filing_date":"2026-07-02"}]}